![](/img/cover-not-exists.png)
Off-Label Use of Biologic Agents in the Treatment of Dermatosis, Part 2: Etanercept, Efalizumab, Alefacept, Rituximab, Daclizumab, Basiliximab, Omalizumab, and Cetuximab
G. Guhl, B. Díaz-Ley, J. Fernández-HerreraVolume:
99
Year:
2008
Language:
english
DOI:
10.1016/s1578-2190(08)70191-4
File:
PDF, 579 KB
english, 2008